Cargando…
SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
[Image: see text] Drug development for specific antiviral agents against coronavirus disease 2019 (COVID-19) is still an unmet medical need as the pandemic continues to spread globally. Although huge efforts for drug repurposing and compound screens have been put forth, only a few compounds are in l...
Autores principales: | Gorshkov, Kirill, Morales Vasquez, Desarey, Chiem, Kevin, Ye, Chengjin, Nguyen Tran, Bruce, Carlos de la Torre, Juan, Moran, Thomas, Chen, Catherine Z., Martinez-Sobrido, Luis, Zheng, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751018/ https://www.ncbi.nlm.nih.gov/pubmed/35036857 http://dx.doi.org/10.1021/acsptsci.1c00182 |
Ejemplares similares
-
A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening
por: Gorshkov, Kirill, et al.
Publicado: (2021) -
Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid
por: Gorshkov, Kirill, et al.
Publicado: (2020) -
Development of a High-Throughput Homogeneous AlphaLISA
Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid
por: Gorshkov, Kirill, et al.
Publicado: (2020) -
Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening
por: Tarpley, Michael, et al.
Publicado: (2021) -
Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes
por: Chiem, Kevin, et al.
Publicado: (2021)